Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Blood (2024) 143 (26): 2804–2807.

https://doi.org/10.1182/blood.2024024452

Published: 2024

Includes: Supplemental data

Journal Articles

Overall and Subgroup Results from the Third Interim Analysis of FIRE, a Real-World Study of Ibrutinib Treatment for CLL/SLL in France

Caroline Dartigeas, Loic Ysebaert, Pierre Feugier, Alain Delmer, Sandrine Dupuis, Marine Deslandes, Marjolein Lahaye, Veronique Leblond

Blood (2022) 140 (Supplement 1): 9906–9907.

https://doi.org/10.1182/blood-2022-155564

Published: 2022

Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer

Blood (2022) 140 (Supplement 1): 7030–7031.

https://doi.org/10.1182/blood-2022-163096

Published: 2022

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study

Loic Ysebaert, Xavier Troussard, Vincent Levy, Ronan Le Calloch, Romain Guieze, Kamel Laribi, Stephane Lepretre, Anne-Sophie Michallet, Véronique Leblond, Pierre Feugier, Elhem Lahjibi, Julien Ramier, Alain Delmer

Blood (2022) 140 (Supplement 1): 12395–12396.

https://doi.org/10.1182/blood-2022-162319

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blood (2022) 140 (Supplement 1): 6631–6632.

https://doi.org/10.1182/blood-2022-159695

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Blood (2021) 138 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2021-147467

Published: 2021

Journal Articles

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Blood (2021) 138 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2021-149640

Published: 2021

Journal Articles

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Blood (2021) 138 (Supplement 1): 637.

https://doi.org/10.1182/blood-2021-152515

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

Radiotherapy (WBRT) or Autologous Stem-Cell Transplantation (ASCT) for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Long-Term Results of the Intergroup Anocef-Goelams Randomized Phase II Precis Study

Blood (2021) 138 (Supplement 1): 658.

https://doi.org/10.1182/blood-2021-146389

Published: 2021

Journal Articles

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2021-145440

Published: 2021

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

Anne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, Loïc Ysebaert, Carole Fleury, Grégory Lazarian, Marie-Sarah Dilhuydy, Delphine Nollet, Romain Guieze, Pierre Feugier, Damien Roos-Weil, Lise Willems, Anne-Sophie Michallet, Alain Delmer, Katia Hormigos, Vincent Levy, Florence Cymbalista, Fanny Baran-Marszak

Blood (2019) 134 (7): 641–644.

https://doi.org/10.1182/blood.2019000854

Published: 2019

Includes: Supplemental data

Journal Articles

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Blood (2018) 132 (1): 49–58.

https://doi.org/10.1182/blood-2017-11-816405

Published: 2018

Includes: Supplemental data

Journal Articles

R-DHA-Oxaliplatin before Autologous Stem Cell Transplantation Prolongs PFS and OS As Compared to R-DHA-Carboplatin and R-DHA-Cisplatin in Patients with Mantle Cell Lymphoma, a Subgroup Analysis of the LyMa Trial

Blood (2017) 130 (Supplement 1): 1496.

https://doi.org/10.1182/blood.V130.Suppl_1.1496.1496

Published: 2017

Journal Articles

Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS)

Blood (2016) 128 (22): 782.

https://doi.org/10.1182/blood.V128.22.782.782

Published: 2016

Journal Articles

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Eric Durot, MD, Cecile Tomowiak, MD, Anne-Sophie Michallet, MD, Jehan Dupuis, MD, Stephane Lepretre, Elise Toussaint, MD, Sophie Godet, Fatiha Merabet, Eric W Van Den Neste, MD PhD, Sarah Ivanoff, Jean-Marc Zini, MD PhD, Caroline Régny, Aurore Perrot, MD, Lukshe Kanagaratnam, Pierre Morel, MD, Veronique Leblond, Alain Delmer, MD PhD

Blood (2016) 128 (22): 2982.

https://doi.org/10.1182/blood.V128.22.2982.2982

Published: 2016

NARROW

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

Overall and Subgroup Results from the Third Interim Analysis of FIRE, a Real-World Study of Ibrutinib Treatment for CLL/SLL in France

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Radiotherapy (WBRT) or Autologous Stem-Cell Transplantation (ASCT) for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Long-Term Results of the Intergroup Anocef-Goelams Randomized Phase II Precis Study

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

R-DHA-Oxaliplatin before Autologous Stem Cell Transplantation Prolongs PFS and OS As Compared to R-DHA-Carboplatin and R-DHA-Cisplatin in Patients with Mantle Cell Lymphoma, a Subgroup Analysis of the LyMa Trial

Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS)

Retrospective Analysis of 56 Cases of Transformed Waldenström Macroglobulinemia. a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only